Skip to content
PubMed This is a summary of 12 peer-reviewed journal articles Updated
Gynecology · Atypical Polypoid Adenomyoma

Diagnostic Pathways & Pathology of APA

At a Glance

Atypical polypoid adenomyoma is a rare uterine growth that imaging can suggest but not confirm. Targeted hysteroscopic sampling gives the pathologist the tissue context needed to identify its characteristic atypical glands and fibromuscular stroma and assess for cancer.

Diagnosing atypical polypoid adenomyoma (APA) is a multi-step process that often starts with imaging but must be confirmed through specialized pathology. Because APA shares features with both benign polyps and certain types of uterine cancer, the way your tissue is collected and analyzed is critical for an accurate diagnosis [1][2].

The Limits of Imaging

You may have first learned of a potential growth through an ultrasound or MRI. While these tools are excellent for finding “polypoid masses” (growths that look like polyps), they cannot definitively identify APA on their own [3][4].

  • Ultrasound: APA often appears as a solid mass with a broad base and increased blood flow (vascularity) [5][6].
  • MRI: This provides a more detailed view of the uterine wall, but because APA’s muscle-like tissue looks similar to the normal uterine wall (myometrium), it can be difficult to tell the two apart [3][4].

Imaging acts as a “scout” to find the lesion, but the “map” for your treatment comes from the pathology report.

Why Hysteroscopy is a Preferred Sampling Method

When a growth is found, doctors must take a tissue sample. There are two main ways to do this: blind sampling (like a D&C or office biopsy) and hysteroscopic-directed sampling. A complete histopathologic examination of an adequate specimen is the diagnostic standard.

For APA, hysteroscopy is strongly preferred for several reasons:

  1. Targeting the Lesion: Because APA is a solid, often stalk-like growth, a blind biopsy tool can slide right past it, entering the space between the mass and the uterine wall. This can result in a “false negative” where the doctor samples normal tissue and misses the lesion entirely [4][7].
  2. Accuracy: Research shows that patients who undergo hysteroscopic removal have lower rates of “residual disease” (leftover cells) and lower rates of recurrence compared to those who have blind procedures [8][9].
  3. Distinguishing from Cancer: A small biopsy might only catch the “atypical” glands without seeing the surrounding muscle-like tissue. This can make it difficult for the pathologist to rule out invasive cancer, as they see “atypical” cells but don’t have enough context to see it is a localized APA [2][10].

The Pathologist’s “Differential Diagnosis”

A pathologist looks at your tissue under a microscope to distinguish APA from three other conditions:

  • Endometrial Intraepithelial Neoplasia (EIN): This is a precancerous condition. While both have “atypical glands,” APA is distinct because those glands are wrapped in thick fibromuscular stroma (muscle and fiber tissue) [1].
  • Benign Adenomyomatous Polyps: These are non-atypical growths. They look like APA but lack the complex, unusual-looking glands [11].
  • Endometrioid Adenocarcinoma: This is a type of cancer. Pathologists distinguish APA from cancer through expert assessment of destructive growth, the tissue’s stromal response, and its relationship to the myometrium. An adequate resection specimen is often needed to assess these features [12][2].

Pathology Report Checklist

When you review your pathology report, look for these key components. Please note that stains are optional adjuncts, and a report is not necessarily inadequate if it does not contain them.

Feature What it Means
Complex Atypical Glands The “active” part of the lesion that requires monitoring [1].
Fibromuscular Stroma The tough, muscle-like “shell” that defines APA [11].
Squamous Morules Small clusters of cells that are a common sign of APA [1].
SATB2 / p16 (Stains) Lab “dyes” that can act as adjuncts to help distinguish APA from invasive cancer [2][10].
SMA (Stain) Sometimes used to confirm the presence of smooth muscle in the lesion [1].
Ki-67 (Stain) Measures how fast cells are dividing; sometimes used as an adjunct alongside other findings [1].

Seeking a Second Opinion

Because APA is rare, many general pathologists may only see a few cases in their entire career. If your report is unclear or if your doctor is unsure if the lesion is cancer, you can request that your slides be sent to a gynecologic pathologist at a specialized cancer center. This expert review is often the most important step in ensuring you receive the right care [2].

Common questions in this guide

Can an ultrasound or MRI confirm atypical polypoid adenomyoma?
No. Ultrasound and MRI can locate a polyp-like uterine mass and show features such as its size, base, or blood flow, but they cannot reliably confirm APA. A tissue specimen examined under a microscope is needed for diagnosis.
Why is hysteroscopy often preferred for diagnosing APA?
During hysteroscopy, the clinician can see the growth and direct the instrument to it or remove it. A blind biopsy or D&C may pass beside a solid, stalk-like lesion and sample normal uterine tissue instead, leading to a false-negative result. A larger targeted specimen also gives the pathologist more context to distinguish APA from cancer.
What findings help confirm APA on a pathology report?
The report typically looks for complex atypical glands surrounded by fibromuscular stroma, the muscle-and-fiber tissue that is characteristic of APA. Squamous morules may also be present. The pathologist uses the full tissue pattern to distinguish APA from EIN and endometrioid adenocarcinoma.
Can atypical polypoid adenomyoma be mistaken for uterine cancer?
Yes. APA can share some atypical gland features with endometrioid adenocarcinoma, especially when the sample is small. An adequate resection specimen may be needed so the pathologist can assess how the glands relate to surrounding tissue and look for destructive growth.
What do stains such as SATB2, p16, SMA, and Ki-67 show in APA?
These are optional laboratory stains that can support the pathologist’s interpretation. SATB2 and p16 may help distinguish APA from invasive cancer, SMA can support the presence of smooth muscle, and Ki-67 indicates how actively cells are dividing. Stains are adjuncts, so a report is not necessarily inadequate if they are not included.
Should my APA pathology slides be reviewed by a specialist?
A second review by a gynecologic pathologist can be helpful because APA is rare and may be confused with EIN or low-grade uterine cancer. It is especially reasonable when the report is unclear or your doctors are uncertain about the diagnosis. The specialist can review the original slides and help guide next steps.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Was my diagnosis based on a blind biopsy or a hysteroscopic resection? If it was blind, how certain are we that the sample represents the whole lesion?
  2. 2.Does my pathology report mention 'complex atypical glands' and 'fibromuscular stroma'? These are key for confirming APA.
  3. 3.Was there any evidence of 'stromal desmoplasia' or a 'cribriform pattern' that might suggest coexisting cancer?
  4. 4.Did the pathologist use specific stains like SATB2 or p16 to help distinguish this from myoinvasive carcinoma?
  5. 5.Based on my imaging, is the lesion's base broad or deep, and how does that affect the safety of a hysteroscopic removal?
  6. 6.Can we have my slides reviewed by a specialized gynecologic pathologist to confirm the distinction from EIN or low-grade cancer?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (12)
  1. 1

    Immunophenotype of Atypical Polypoid Adenomyoma of the Uterus: Diagnostic Value and Insight on Pathogenesis.

    Travaglino A, Raffone A, Saccone G, et al.

    Applied immunohistochemistry & molecular morphology : AIMM 2020; (28(8)):646-653 doi:10.1097/PAI.0000000000000780.

    PMID: 31855579
  2. 2

    Patterns of SATB2 and p16 reactivity aid in the distinction of atypical polypoid adenomyoma from myoinvasive endometrioid carcinoma and benign adenomyomatous polyp on endometrial sampling.

    Worrell HI, Sciallis AP, Skala SL

    Histopathology 2021; (79(1)):96-105 doi:10.1111/his.14338.

    PMID: 33459390
  3. 3

    Atypical Polypoid Adenomyoma in a Patient with Hyperprolactinemia: a Novel Case and Systematic Review of the Systematic Reviews.

    Peitsidis P, Vlachadis N, Zervoudis S, et al.

    Maedica 2025; (20(4)):877-886 doi:10.26574/maedica.2025.20.4.877.

    PMID: 41537068
  4. 4

    MRI and Transvaginal Ultrasound Findings of Atypical Polypoid Adenomyoma: A Case Report.

    Tan Y, Hu X, Song X, Zhang WJ

    Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih 2022; (37(1)):82-86 doi:10.24920/003911.

    PMID: 35256047
  5. 5

    The role of three-dimensional power Doppler hysterosonography (3-DPDS) in distinguishing atypical polypoid adenomyomas (APAs) from other intrauterine tumors: correlation with pathologic findings.

    Kalmantis K, Daskalakis G, Semertzidou A, Rodolakis A

    Archives of gynecology and obstetrics 2017; (296(2)):391-396 doi:10.1007/s00404-017-4436-3.

    PMID: 28664484
  6. 6

    Surgical treatment of a rare case of atypical polypoid adenomyoma of the uterus in a menopausal patient: a case report.

    Thanasa EI, Thanasa AI, Paraoulakis IE, et al.

    The Pan African medical journal 2023; (44()):118 doi:10.11604/pamj.2023.44.118.39256.

    PMID: 37275297
  7. 7

    A case of rapidly-growing atypical polypoid adenomyoma which was histologically diagnosed before operation and removed by a laparoscopic resection.

    Nakabayashi A, Takahashi N, Hashimoto K, et al.

    Taiwanese journal of obstetrics & gynecology 2018; (57(1)):115-118 doi:10.1016/j.tjog.2017.12.019.

    PMID: 29458879
  8. 8

    Atypical polypoid adenomyoma follow-up and management: Systematic review of case reports and series and meta-analysis.

    Biasioli A, Londero AP, Orsaria M, et al.

    Medicine 2020; (99(26)):e20491 doi:10.1097/MD.0000000000020491.

    PMID: 32590732
  9. 9

    Management of women with atypical polypoid adenomyoma of the uterus: A quantitative systematic review.

    Raffone A, Travaglino A, Saccone G, et al.

    Acta obstetricia et gynecologica Scandinavica 2019; (98(7)):842-855 doi:10.1111/aogs.13553.

    PMID: 30714089
  10. 10

    Stromal p16 and SATB2 Expression Does Not Distinguish Atypical Polypoid Adenomyoma (APA) From its Benign Mimics.

    Bui CM, Azimpouran M, Balzer B, et al.

    International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 2024; (43(6)):586-594 doi:10.1097/PGP.0000000000001023.

    PMID: 38833724
  11. 11

    Atypical polypoid adenomyoma of the uterus: A reappraisal of the clinicopathological and immunohistochemical features.

    Lu B, Yu M, Shi H, Chen Q

    Pathology, research and practice 2019; (215(4)):766-771 doi:10.1016/j.prp.2019.01.016.

    PMID: 30661903
  12. 12

    Clinicopathological Characteristics of Atypical Polypoid Adenomyoma of the Uterus in Association With Endometrial Atypical Hyperplasia and Endometrioid Carcinoma.

    Kim T, Cho YA, Kim HS

    In vivo (Athens, Greece) 2025; (39(6)):3539-3551 doi:10.21873/invivo.14152.

    PMID: 41167709

This page explains the diagnosis and pathology of atypical polypoid adenomyoma for informational purposes only and does not constitute medical advice. Your gynecologist and gynecologic pathologist should interpret your imaging and pathology and guide your care.

Get notified when new evidence is published on uterine corpus atypical polypoid adenomyoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.